Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Novel biomarkers and emerging therapies for sickle cell disease

Raffaella Colombatti • 11 Jun 2022
EHA 2022
Non-Malignant Sickle Cell Disease

Raffaella Colombatti, MD, PhD, University of Padova, Padova, Italy discusses the importance of taking a multi-omics approach for the diagnosis and treatment of sickle cell disease (SCD), namely using clinical, hematological, and genetic data, together with imaging data. Dr Colombatti comments on using artificial intelligence (AI) in order to explore novel biomarkers for SCD and using this data to optimize patient treatment and open an avenue for a personalized medicine approach. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Raffaella Colombatti

1:21
The use of radiomics and artificial intelligence for sickle cell disease
Raffaella Colombatti • 11 Jun 2022
1:45
Towards a personalized treatment approach for SCD
Raffaella Colombatti • 11 Jun 2022

Related Videos

2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
1:23
Developing a PRO collection tool for patients with SCD: key themes which are important to patients
Nirmish Shah • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals